前药
组蛋白脱乙酰基酶
药物输送
肽
材料科学
癌细胞
喜树碱
组蛋白
纳米技术
癌症研究
生物物理学
癌症
生物化学
生物
化学
基因
遗传学
作者
Haoyu Bai,Huifang Wang,Zhuha Zhou,Ying Piao,Xiangrui Liu,Jianbin Tang,Xian Shen,Youqing Shen,Zhuxian Zhou
标识
DOI:10.1002/adfm.202214025
摘要
Abstract Precise delivery and release of therapeutics in the subcellular targets are critical for tumor‐selective chemotherapy. Self‐immolative structures are sophisticatedly designed to achieve stimuli‐responsive drug delivery. Herein, the facile fabrication of self‐immolative peptide‐camptothecin (CPT) nanoassemblies is reported for cancer‐selective drug delivery by utilizing the dual‐mode peptide targeting design and amine‐catalyzed intramolecular hydrolysis. The dual‐mode peptide targeting design is realized by co‐assembly of tumor targeting and nuclei‐localizing peptide‐CPT prodrugs, rendering the nanoassemblies with efficient cancer cell‐selective capability. When the nanoassemblies enter cancer cell, the overexpressed endonuclear histone deacetylases (HDACs) cleave the acetyl group to generate primary amines, triggers amine‐catalyzed intramolecular hydrolysis, and fast‐release drug in the cell nuclei. The peptide‐CPT prodrugs release up to 68% CPT in 1 h in the presence of HDACs, while no detectable CPT release is observed in the absence of HDACs at the same time. The peptide‐CPT prodrugs selectively kill cancer cells with high HDACs levels. The dual targeting peptide‐CPT nanoassemblies exhibit extended blood circulation, excellent tumor accumulation, and potent antitumor activity by inhibiting tumor progression and metastasis in mice bearing 4T1 aggressive breast tumors. Overall, the HDAC‐triggered self‐immolative strategy is promising for developing cancer‐selective drug delivery systems.
科研通智能强力驱动
Strongly Powered by AbleSci AI